A team led by UCL researchers with Great Ormond Street Hospital (GOSH) and Moorfields Eye Hospital, found B cells—alongside T ...

While interested in CAR-T therapies’ potential to achieve durable, drug-free remission in serious autoimmune conditions, the ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical ...

Daiichi Sankyo begins patient dosing in phase 1/2 trial of DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: Tokyo Friday, February 6, 2026, 10:00 Hrs [I ...

Investor enthusiasm and evolving FDA pathways are accelerating rare disease drug development, with ultrarare conditions like ...

Broadly neutralizing antibodies, or bnAbs, are a long‑standing goal of HIV vaccine research because they can disable many strains of the virus at once.

UK scientists have explored the role of B cells and T cells in the development of uveitis among patients with juvenile idiopathic arthritis ...

WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with ...

Discover how Laverdia CA1 (verdinexor) treats canine lymphoma. Learn about the mechanism of action, handling precautions, and ...

Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programsVispa-cel (CB-010) ANTLER phase 1 translational and clinical data ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 3, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company ...